Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 27-Mar-24 8:28 PM View:  | Zanganeh Maky Chief Executive Officer Director | Summit Therapeutics Inc. (SMMT) | 27-Mar-24 | Purchase | 54,321 | $3.72 | $201,874.00 | < 1% 25.44M to 25.49M | |
| 27-Mar-24 8:28 PM View: | Zanganeh Maky Chief Executive Officer Director | Summit Therapeutics Inc. (SMMT) | 27-Mar-24 | Purchase | 26,000 | $3.72 | $96,720.00 | < 1% 25.41M to 25.44M | |
| 27-Mar-24 8:27 PM View: | Dhingra Ankur Chief Financial Officer | Summit Therapeutics Inc. (SMMT) | 26-Mar-24 | Private Purchase | 100,000 | $3.75 | $375,000.00 | 39% 254.96K to 354.96K | |
| 27-Mar-24 8:28 PM View: | Zanganeh Maky Chief Executive Officer Director | Summit Therapeutics Inc. (SMMT) | 26-Mar-24 | Private Purchase | 30,000 | $3.75 | $112,500.00 | < 1% 25.38M to 25.41M | |
| 13-Dec-23 4:49 PM View: | Dhingra Ankur Chief Financial Officer | Summit Therapeutics Inc. (SMMT) | 13-Dec-23 | Private Purchase | 20,400 | $2.17 | $44,254.00 | 9% 234.56K to 254.96K | |
| 13-Dec-23 5:11 PM View: | Zanganeh Maky Chief Executive Officer Director | Summit Therapeutics Inc. (SMMT) | 12-Dec-23 | Purchase | 5,000 | $2.07 | $10,350.00 | < 1% 25.38M to 25.38M | |
| 13-Dec-23 5:11 PM View: | Zanganeh Maky Chief Executive Officer Director | Summit Therapeutics Inc. (SMMT) | 11-Dec-23 | Exercise (in-the money or at-the-money) | 315,681 | $1.58 | $498,776.00 | 1% 25.06M to 25.38M | |
| 13-Dec-23 5:11 PM View: | Zanganeh Maky Chief Executive Officer Director | Summit Therapeutics Inc. (SMMT) | 11-Dec-23 | Exercise (in-the money or at-the-money) | 489,814 | $1.44 | $705,332.00 | 2% 24.57M to 25.06M | |
| 16-Oct-23 4:06 PM View: | Soni Manmeet Singh Chief Operating Officer Director | Summit Therapeutics Inc. (SMMT) | 13-Oct-23 | Private Purchase | 2,976,190 | $1.68 | $5,000,000.00 | 100% 0 to 2.98M | |
| 08-Mar-23 9:31 PM View: | Zanganeh Maky Co-CEO & President Director | Summit Therapeutics Inc. (SMMT) | 08-Mar-23 | Purchase | 7,553,300 | $1.05 | $7,930,970.00 | 28% 26.9M to 34.46M | |
| 08-Mar-23 9:31 PM View: | Zanganeh Maky Co-CEO & President Director | Summit Therapeutics Inc. (SMMT) | 08-Mar-23 | Private Purchase | 15,973,700 | $1.05 | $16,772,400.00 | 146% 10.93M to 26.9M | |
| 08-Mar-23 5:24 PM View: | Dhingra Ankur Chief Financial Officer | Summit Therapeutics Inc. (SMMT) | 07-Mar-23 | Private Purchase | 196,362 | $1.05 | $206,180.00 | 253% 77.72K to 274.08K | |
| 14-Feb-24 10:00 PM View: | Xia Yu Director | Summit Therapeutics Inc. (SMMT) | 07-Mar-23 | Purchase | 21,523,500 | $1.05 | $22,599,700.00 | 100% 0 to 21.52M | |
| 08-Mar-23 4:12 PM View: | Duggan Robert W Chief Executive Officer Director | Summit Therapeutics Inc. (SMMT) | 06-Mar-23 | Private Purchase | 376,489,984 | $1.05 | $395,313,984.00 | 214% 175.86M to 552.35M | |
| 14-Feb-24 10:00 PM View: | Xia Yu Director | Summit Therapeutics Inc. (SMMT) | 17-Jan-23 | Private Purchase | 10,000,000 | $2.51 | $25,100,000.00 | 100% 0 to 10.0M | |
| 09-Dec-22 6:22 PM View: | Zanganeh Maky Co-CEO & President Director | Summit Therapeutics Inc. (SMMT) | 06-Dec-22 | Acquisition (other) | 373,857 | -- | -- | 4% 10.56M to 10.93M | |
| 08-Dec-22 6:28 PM View: | Duggan Robert W Chief Executive Officer Director | Summit Therapeutics Inc. (SMMT) | 06-Dec-22 | Acquisition (other) | 9,346,430 | -- | -- | 6% 162.53M to 171.88M | |
| 17-Aug-22 4:49 PM View: | Dhingra Ankur Chief Financial Officer | Summit Therapeutics Inc. (SMMT) | 16-Aug-22 | Purchase | 24,658 | $0.97 | $23,918.30 | 48% 51.59K to 76.25K | |
| 18-Aug-22 4:36 PM View: | Zanganeh Maky Co-CEO & President Director | Summit Therapeutics Inc. (SMMT) | 16-Aug-22 | Private Purchase | 184,430 | $0.97 | $178,897.00 | 4% 4.75M to 4.93M | |
| 18-Aug-22 4:36 PM View: | Zanganeh Maky Co-CEO & President Director | Summit Therapeutics Inc. (SMMT) | 16-Aug-22 | Purchase | 5,624,700 | $0.97 | $5,455,960.00 | 114% 4.93M to 10.56M | |
| 18-Aug-22 4:38 PM View: | Duggan Robert W Chief Executive Officer Director | Summit Therapeutics Inc. (SMMT) | 16-Aug-22 | Private Purchase | 94,849,200 | $0.97 | $92,003,696.00 | 140% 67.68M to 162.53M | |
| 17-Aug-22 4:49 PM View: | Dhingra Ankur Chief Financial Officer | Summit Therapeutics Inc. (SMMT) | 16-Aug-22 | Private Purchase | 11,557 | $0.97 | $11,210.30 | 29% 40.04K to 51.59K | |
| 25-May-22 8:45 PM View: | Duggan Robert W Chief Executive Officer Director | Summit Therapeutics Inc. (SMMT) | 23-May-22 | Acquisition (other) | 21,135 | -- | -- | < 1% 67.66M to 67.68M | |
| 14-May-21 4:39 PM View: | Duggan Robert W Chief Executive Officer Director 10% Owner | Summit Therapeutics Inc. (SMMT) | 12-May-21 | Market Purchase | 11,365,900 | $5.24 | $59,557,400.00 | 20% 56.3M to 67.66M | 4% |
| 14-May-21 4:37 PM View: | Zanganeh Maky Chief Operating Officer Director | Summit Therapeutics Inc. (SMMT) | 12-May-21 | Market Purchase | 389,077 | $5.24 | $2,038,760.00 | 9% 4.36M to 4.75M | 4% |
| 01-Dec-20 7:45 PM View: | Powell David Jonathan Chief Scientific Officer | Summit Therapeutics Inc. (SMMT) | 30-Nov-20 | Option Exercise | 13,713 | $1.79 | $24,546.30 | 100% 0 to 13.71K | |
| 01-Dec-20 7:45 PM View: | Powell David Jonathan Chief Scientific Officer | Summit Therapeutics Inc. (SMMT) | 30-Nov-20 | Option Sale | 13,713 | $4.44 | $60,885.70 | (100%) 13.71K to 0 | |
| 01-Dec-20 7:45 PM View: | Powell David Jonathan Chief Scientific Officer | Summit Therapeutics Inc. (SMMT) | 27-Nov-20 | Option Exercise | 29,569 | $1.86 | $55,088.60 | 100% 0 to 29.57K | |
| 01-Dec-20 7:45 PM View: | Powell David Jonathan Chief Scientific Officer | Summit Therapeutics Inc. (SMMT) | 27-Nov-20 | Option Sale | 29,569 | $4.39 | $129,808.00 | (100%) 29.57K to 0 | |
| 25-Nov-20 7:51 PM View: | Powell David Jonathan Chief Scientific Officer | Summit Therapeutics Inc. (SMMT) | 25-Nov-20 | Option Sale | 12,070 | $4.32 | $52,142.40 | (100%) 12.07K to 0 | |
| 25-Nov-20 7:51 PM View: | Powell David Jonathan Chief Scientific Officer | Summit Therapeutics Inc. (SMMT) | 25-Nov-20 | Option Exercise | 12,070 | $1.92 | $23,174.40 | 100% 0 to 12.07K | |
| 25-Nov-20 7:51 PM View: | Powell David Jonathan Chief Scientific Officer | Summit Therapeutics Inc. (SMMT) | 24-Nov-20 | Option Exercise | 11,374 | $1.92 | $21,838.10 | 100% 0 to 11.37K | |
| 25-Nov-20 7:51 PM View: | Powell David Jonathan Chief Scientific Officer | Summit Therapeutics Inc. (SMMT) | 24-Nov-20 | Option Sale | 11,374 | $4.21 | $47,884.50 | (100%) 11.37K to 0 | |
| 25-Nov-20 7:51 PM View: | Powell David Jonathan Chief Scientific Officer | Summit Therapeutics Inc. (SMMT) | 23-Nov-20 | Option Exercise | 6,987 | $1.92 | $13,415.00 | 100% 0 to 6.99K | |
| 25-Nov-20 7:51 PM View: | Powell David Jonathan Chief Scientific Officer | Summit Therapeutics Inc. (SMMT) | 23-Nov-20 | Option Sale | 6,987 | $4.40 | $30,742.80 | (100%) 6.99K to 0 | |
| 10-Nov-20 4:25 PM View: | Duggan Robert W Chief Executive Officer Director 10% Owner | Summit Therapeutics Inc. (SMMT) | 06-Nov-20 | Purchase | 14,071,900 | $3.34 | $47,000,000.00 | 33% 42.22M to 56.3M |
